If concluded, the Symbiotec transaction will be Actis’s second major exit in six years. Photo: Company websiteMumbai: Private equity firm Actis Capital is looking to sell its majority stake in Indore-based Symbiotec Pharmalab Ltd, according to two people familiar with the development. The deal would value Symbiotec at $400 million, with London-based Actis, which owns 70%, standing to make $280 million, one of the two said on condition of anonymity. The healthcare sector has been an investment favourite for private equity investors in India, offering sizeable returns and easy exits. Most of the bets in Indian drug makers by private equity funds have paid off.

Source: Mint September 11, 2016 19:30 UTC